8-K: Fortress Biotech Reports First Quarter 2025 Financial Results, Checkpoint Therapeutics Acquisition by Sun Pharma Imminent

Fortress Biotech announces its Q1 2025 financial results, highlighting the upcoming acquisition of Checkpoint Therapeutics by Sun Pharma and the commercial launch of Emrosi.

Summary

• Fortress Biotech reported its Q1 2025 financial results, with a consolidated net product revenue of $13.1 million, slightly up from $13.0 million in Q1 2024.
• The company's consolidated net loss attributable to common stockholders was $(12.7) million, or $(0.48) per share, compared to a net loss of $(17.9) million, or $(1.04) per share, for the same period last year.
• Checkpoint Therapeutics is set to be acquired by Sun Pharma, with a special meeting of Checkpoint stockholders scheduled for May 28, 2025, to approve the transaction.
• The commercial launch of Emrosi for rosacea treatment has commenced, with initial prescriptions filled at the end of March 2025.
• The FDA accepted the New Drug Application for CUTX-101 for priority review, with a PDUFA goal date of September 30, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the upcoming acquisition of Checkpoint, the FDA approvals, and the increase in cash position. However, the net loss and increased SG&A expenses temper the overall sentiment.

Positives

• Fortress Biotech's cash position increased by $34.0 million during the quarter, reaching $91.3 million as of March 31, 2025.
• The acquisition of Checkpoint Therapeutics by Sun Pharma is expected to provide Fortress with approximately $28 million at closing, future potential royalties, and a potential CVR payment.
• The FDA's priority review of CUTX-101 and the potential for a Priority Review Voucher upon approval are positive developments.
• The commercial launch of Emrosi represents a new revenue stream for the company.
• Net loss attributable to common stockholders decreased from $(17.9) million to $(12.7) million.

Negatives

• The company reported a net loss attributable to common stockholders of $(12.7) million for Q1 2025.
• Selling, general and administrative costs increased to $25.7 million for the first quarter ended March 31, 2025, compared to $17.9 million for the first quarter ended March 31, 2024.

Risks

• The closing of the Checkpoint Therapeutics acquisition is subject to various conditions, and there is no guarantee that it will close in a timely manner or at all.
• The company's growth strategy relies on acquiring and developing product candidates, which involves inherent risks and uncertainties.
• The company needs substantial additional funds, and there are uncertainties relating to financings.
• The company's ability to successfully commercialize products and receive royalties depends on various factors, including regulatory approval and market acceptance.

Future Outlook

Fortress is focused on key value drivers, including the PDUFA action date for CUTX-101 and the commercial launch of Emrosi, positioning the company for continued revenue growth and value-driving milestones.

Management Comments

• Fortress entered 2025 with strong momentum following a transformational fourth quarter marked by the U.S. Food and Drug Administration (FDA) approvals of Emrosi and UNLOXCYT, and the acceptance of the New Drug Application (NDA) for CUTX-101.
• These outcomes continue to validate Fortress business model identifying, developing, and advancing innovative therapies with strategic optionality for value creation.
• We remain committed to delivering innovative therapies to patients while building long-term shareholder value.

Industry Context

The acquisition of Checkpoint Therapeutics by Sun Pharma reflects the ongoing consolidation in the biopharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates to expand their portfolios and market reach. The FDA approvals of Emrosi and UNLOXCYT highlight the increasing focus on innovative therapies for dermatology and oncology.

Comparison to Industry Standards

• Journey Medicals net product revenues for the first quarter ended March 31, 2025, were $13.1 million, compared to net product revenues of $13.0 million for the first quarter ended March 31, 2024, which is a modest increase.
• Other companies in the dermatology space, such as Galderma and Bausch Health, have significantly higher revenues, indicating that Journey Medical is still a smaller player in the market.
• The acquisition of Checkpoint Therapeutics by Sun Pharma is similar to other acquisitions in the biopharmaceutical industry, such as Pfizer's acquisition of Arena Pharmaceuticals, where larger companies acquire smaller companies with promising drug candidates.

Stakeholder Impact

• Shareholders may benefit from the Checkpoint acquisition and potential future royalties.
• Patients may benefit from the commercial availability of Emrosi and UNLOXCYT.
• Employees of Checkpoint may experience changes as a result of the acquisition by Sun Pharma.

Next Steps

• Checkpoint stockholders will vote on the acquisition by Sun Pharma on May 28, 2025.
• The company awaits the FDA's decision on CUTX-101, with a PDUFA goal date of September 30, 2025.
• Fortress will continue the commercial launch of Emrosi.
• Fortress will continue to identify and evaluate biopharmaceutical compounds using artificial intelligence for potential acquisition or licensing.

Key Dates

Keywords

Fortress Biotech, Checkpoint Therapeutics, Sun Pharma, Emrosi, CUTX-101, UNLOXCYT, Financial Results, Acquisition, PDUFA, Biopharmaceutical